OnThePharm thinks so. The GLP-1 based therapies are an exciting new class of diabetes medications. So far, Byetta has worked well for my patients – the jury is still out with Januvia. Merck certainly hopes that Januvia will rescue them.
Real physician voices, twice a week
Free, and one click to unsubscribe.


